Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Virginia Bluthgen"'
Autor:
Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, Maria-Virginia Bluthgen, Romain Perallon, Lara Chalabreysse, Anne De Muret, Veronique Hofman, Alexander Marx, Marie Parrens, Veronique Secq, Vincent Thomas de Montpreville, Françoise Galateau-Salle, Pierre Brousset, Julie Milia, Nicolas Girard, Benjamin Besse, Thierry Jo Molina, Julien Mazières
Publikováno v:
Biomarker Research, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC w
Externí odkaz:
https://doaj.org/article/2146e8849ab54a3a9f789f3cef96aa72
Publikováno v:
European Respiratory Review, Vol 24, Iss 138, Pp 582-593 (2015)
In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy
Externí odkaz:
https://doaj.org/article/32a51e094084499ba43bc82be333572a
Autor:
Gonzalo Recondo, Matías Cerini, Victoria Faura, Maria Virginia Bluthgen, Aldo Perfetti, Martin Naveira, Carlos Silva, L. Lupinacci, Nicolás Minatta, Florencia Rizzi, Alejandro Kuzminin, Manglio Miguel Rizzo, Alejandro J. Videla
Publikováno v:
International journal of clinical oncology. 26(6)
Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status (PS) are underrepresented in clinical trials. We evaluate the efficacy and safety of ICIs in a real-w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d26e74d49d80f27b90acee1144227ea5
https://pubmed.ncbi.nlm.nih.gov/33715058
https://pubmed.ncbi.nlm.nih.gov/33715058
Autor:
Anas Gazzah, David Planchard, Lambros Tselikas, Nathalie Lassau, Etienne Rouleau, Melodie Tazdait, Alison Dormieux, Caroline Caramella, Cécile Le Péchoux, Jordi Remon, Laura Mezquita, Paul Henry Cournede, Francesco Facchinetti, Frank Aboubakar, Ludovic Lacroix, Charles Naltet, Corinne Balleyguier, Julien Adam, Maria-Virginia Bluthgen, Pernelle Lavaud, Benjamin Besse
Publikováno v:
European Radiology
European Radiology, Springer Verlag, 2020, 30 (9), pp.5021-5028. ⟨10.1007/s00330-020-06784-y⟩
European radiology, Vol. 30, no. 9, p. 5021-5028 (2020)
European Radiology, Springer Verlag, 2020, 30 (9), pp.5021-5028. ⟨10.1007/s00330-020-06784-y⟩
European radiology, Vol. 30, no. 9, p. 5021-5028 (2020)
OBJECTIVES: The aim of our study was to investigate the association between driver oncogene alterations and metastatic patterns on imaging assessment, in a large cohort of metastatic lung adenocarcinoma patients. METHODS: From January 2010 to May 201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::691eccb1b635be7a7f8caeff921dd193
https://hal-centralesupelec.archives-ouvertes.fr/hal-03127555
https://hal-centralesupelec.archives-ouvertes.fr/hal-03127555
Publikováno v:
Future oncology (London, England). 16(23)
Immune checkpoint inhibitors directed against CTLA-4, PD-1 and PD-L1 have transformed the treatment of patients with cancer. Immunotherapy regimens have evolved from a single agent approach to the combination of immune checkpoint inhibitors like anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e213302075395410516ff4c8af7be590
https://pubmed.ncbi.nlm.nih.gov/32501724
https://pubmed.ncbi.nlm.nih.gov/32501724